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Hepatic and extrahepatic factors contribute to mortality related to liver cirrhosis 
and therefore much research is still to be done in order to understand the condi-
tion thoroughly and to possibly intervene in the process. It is considered that the 
currently applied prognostic scores are not ideal mortality predictors. On the other 
hand, recent scientific concepts have revealed the significant contributing role of 
endothelial dysfunction and of systemic inflammation in the pathogenesis of portal 
hypertension. Consequently, these concepts are inevitably leading towards propos-
ing and validating new prognostic indicators in cirrhotic patients. Von-Willebrand 
factor as an indicator of endothelial dysfunction and C-reactive protein as a surro-
gate marker of systemic inflammation and several other parameters and biological 
markers have been emerging as a relevant and potentially useful prognostic indica-
tors. Also, the coagulopathy associated to liver disease is in close relation with these 
entities and still an important research topic. Despite the promising data regarding 
their prognostic potential, additional research is needed in order to define and 
validate their value more precisely in clinical and prognostic settings.
Keywords: cirrhosis, portal hypertension, endothelial dysfunction,  
systemic inflammation, von-Willebrand factor, CRP, coagulopathy
1. Introduction
Liver cirrhosis represents the final stage of chronic liver disease which denotes 
reduced hepatic cell mass, formation of regenerative nodules and progressive fibro-
sis. The altered hepatic architecture leads to an impaired hepatic haemodynamics 
that manifests with portal hypertension (PH) and gradually leads to development 
of liver failure [1, 2]. PH is an accompanying condition of the natural course of 
chronic liver disease and a key factor underlying most of the complications that 
often determine the prognosis in these patients [3]. Although the development of 
PH has been mainly attributed to the elevated hydrostatic pressure due to increased 
vascular resistance, different perspectives have recently emerged regarding this 
topic. Endothelial dysfunction (ED), a state that indicates irregular function of 
the endothelial cell (EC), seems to have an important role in the increased vascular 
tone of the hepatic microcirculation [4, 5] and is an important factor involved in 
Portal Hypertension - Recent Advances
2
the development of PH [6]. It is also considered that elevated von Willebrand factor 
(vWF) contributes to the presence of a subtle hypercoagulable state that worsens 
the PH [7]. Chronic liver disease has also been related to many complex abnor-
malities in all segments of the haemostatic process. Moreover, the simultaneous 
impairment in the procoagulant and anticoagulant activity and the increased vWF 
concentration transform liver cirrhosis into a condition that is characterized by a 
globally rebalanced hemostasis [8].
2.  Portal hypertension: definition, diagnostic criteria, clinical and 
prognostic significance
PH is an entity that indicates elevated hydrostatic pressure in the portal vein 
that initially occurs as a result of the structural abnormalities in the hepatic vascu-
lature [6]. The increased vascular inflow which develops as a consequence of the 
splanchnic vasodilation and of the increased cardiac “output” also contribute in 
the progressivon of PH [9]. The main diagnostic criterion for PH is the presence of 
elevated hepatic venous pressure gradient (HVPG). HVPG denotes the pressure 
gradient between the so-called “wedged” pressure and the free pressure of the 
hepatic veins, which actually reflects the pressure gradient between the portal vein 
and the inferior vena cava. The HVPG value correlates with PH-related complica-
tions [10] and the HVPG measurement is used in therapeutic as well as in prognostic 
purposes [11]. Clinically significant portal hypertension is defined as the presence 
of HVPG ≥10 mmHg and it indicates an increased risk of complications and death 
associated with liver disease and an increased risk of hepatocellular carcinoma 
[12–15]. HVPG ≥12 mmHg carries an increased risk of variceal bleeding, and HVPG 
≥20 mmHg is associated with poor clinical outcomes in cirrhotic patients [12–15]. 
The PH-related complications are often life-threatening conditions associated with 
high morbidity and mortality [3] and hence early diagnosis and appropriate treat-
ment is essential for improving the prognosis in these patients [16]. Although HVPG 
measurement is the gold standard for determining the presence and extent of PH, 
this diagnostic procedure is not widely used in the everyday clinical practice. It is 
invasive, expensive and due to technical reasons in about 4% of patients it could be 
unsuccessful [17]. Consequently, these limitations also preclude the widespread use 
of the diagnostic and therapeutic algorithms that rely on pressure-based diagnostics. 
Therefore, the Baveno V Consensus for portal hypertension encourages research 
towards defining new, non-invasive indicators of PH with better sensitivity and 
specificity than the ones that are currently used [16, 18].
The natural course of chronic liver disease is characterized by two phases. The 
first compensated phase is followed by a rapidly progressing, decompensated 
phase characterized by the presence of complications of PH and/or hepatic dys-
function [1]. As the disease progresses, portal pressure increases and liver func-
tion decreases, leading to development of ascites, hypertensive gastrointestinal 
bleeding, encephalopathy, and jaundice [1]. The occurrence of any complication 
of PH defines the transition from a compensated to a decompensated phase [1]. 
The occurrence of ascites is the most common initial complication of PH in cir-
rhotic patients [19] and it is usually considered a hallmark of the decompensated 
phase [1]. By combining data from two large studies involving 1649 patients that 
analyzed the natural course of the disease [19, 20], four clinical stages of cir-
rhosis were defined, each with a different clinical presentation and a significantly 
different prognosis [1]. Stage 1 is characterized by the absence of esophageal 
varices and ascites (mortality rate about 1% per year); stage 2 is characterized by 
the presence of esophageal varices but without bleeding or ascites (mortality rate 
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3.4% per year); stage 3 is characterized by the presence of ascites with or without 
varices in a patient who has never bleed (mortality rate 20% per year) and stage 
4 is characterized by gastrointestinal bleeding with or without ascites (mortality 
rate 57% per year). Stages 1 and 2 correspond to compensated and stages 3 and 4 
to decompensated cirrhosis [1]. The transition from compensated to decompen-
sated phase occurs at a rate of 5–7% per year [21, 22] and with the onset of the 
first episode of decompensation the life expectancy of patients is significantly 
shortened [1]. Median survival is significantly shorter in patients with decompen-
sated than in patients with compensated cirrhosis (approximately 2 years versus 
over 12 years) [1]. Consequently, the prognostic indicators used in both stages are 
different and have different prognostic significance [23, 24].
3.  The role of endothelial dysfunction in the pathogenesis of portal 
hypertension
EC has a potential for producing many different mediators that are crucial for 
proper regulation of the vascular homeostasis, the vasomotor tone and for many 
inflammatory, metabolic and hemostatic processes in the body [25]. EC regulates the 
vascular tone by its ability to release vasoactive substances, including vasodilators 
such as nitric oxide (NO) and prostacyclin and vasoconstrictors such as thromboxane 
A2 (TXA2) [9]. Endothelial activation is a broad term implying EC function changes 
occurring as a response to a number of different stimuli. As a response to vascular 
stress, infections or hypoxia, the EC undergoes certain changes that lead to an 
imbalance in the release of vasoactive mediators predisposing development of a pro-
inflammatory and pro-coagulant state [26–32]. As a response to chronic, continuous 
exposure of the EC to various physical or chemical stimuli a disturbance in the func-
tion of the EC occurs, a state defined as ED. [25]. ED is a condition of imbalanced 
release of vasoconstrictors and vasodilators, stimulators and inhibitors of growth, 
proatherogenic and antiatherogenic, and pro-coagulant and anticoagulant media-
tors [4, 25]. It has been established that ED is an early key event in many vascular 
diseases [5] and its presence is generally associated with a poor prognosis [7]. Also, 
ED is an early event that has been involved in the pathogenesis of PH [6]. ED as part 
of the liver disease occurs in the liver microcirculation and in the EC in the systemic 
and splanchnic circulation. Hepatic inflammation in early cirrhosis is the primary 
trigger that causes damage to the hepatic reticuloendothelial system and leads to 
intrahepatic ED [33–41]. This ED is manifested by an increased release of vaso-
constrictive substances leading to impaired flow-associated endothelial-dependent 
vascular relaxation, i.e., to inadequate postprandial vasodilation. Intrahepatic ED is 
considered to be the primary disorder that leads to increased intrahepatic vascular 
resistance and progressive PH [4, 5, 9, 42], and later, to a consequent arterial vasodi-
lation in the splanchnic circulation [4, 43–45]. On the contrary, in advanced disease, 
endotoxemia is considered to be the main factor responsible for the development of 
ED in the systemic circulation. The systemic ED is manifested by an increased pro-
duction of vasodilator molecules, mainly NO [46, 47], a vasodilator that is secreted 
by the endothelial and vascular smooth muscle cells [48] and that also has certain 
anti-inflammatory and antithrombotic properties [7]. The increased vasodilator tone 
in the systemic circulation leads to increased endothelial-dependent relaxation and 
increased blood flow, which consequently leads to the development of hyperdynamic 
circulation (HC) [49–51].
As a result of the vascular stress and increased concentration of some circula-
tory factors such as catecholamines, estrogens, and substance P that stimulate the 
endothelial synthetic activity [52, 53] several typical hemodynamic disorders occur 
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in cirrhotic patients. The HC is one of the main and most typical hemodynamic 
features of patients with liver cirrhosis and PH [54–57]. It occurs as a result of a 
specific combination of several hemodynamic abnormalities, but the increased NO 
production is considered to be the major factor in the development of HC [54–57]. 
In this context, some studies have confirmed a significant correlation between 
the level of vWF and the NO production which may suggest a common activation 
mechanism [27]. HC is characterized by increased intrahepatic vascular resistance 
as a result of intrahepatic vasoconstriction and increased systemic vasodilation 
leading to an increased portal flow. The presence of HC in patients with liver cir-
rhosis is manifested by hypotension, low vascular resistance, and increased cardiac 
output, which develops as a compensation of the systemic vasodilation [9, 58]. 
Additionally, increased portal systemic shunting and reduced renal flow also occur 
[3, 59]. The severity of the HC has been significantly associated with the degree of 
PH, that is, by activating the NO synthetase, the portal pressure is an important 
factor that regulates the vasodilation in the splanchnic circulation [60]. Hence, in 
patients with liver cirrhosis, in addition to the endotoxemia, PH is thought to act 
as a factor of increased endothelial stress and stimulates additional NO produc-
tion [52], i.e., the PH indirectly emphasizes the vasodilation in the splanchnic 
circulation.
4.  Von-willebrand factor as an indicator of endothelial dysfunction and 
factor of PH progression
Some mediators secreted by the activated EC such as NO, vWF, P-selectin and 
Isoprostran are used as indicators of ED [26, 29, 61–63]. The important role of vWF 
in the process of angiogenesis, inflammation, cell proliferation and tumor growth 
has recently been increasingly emphasized [64]. Considering the fact that liver 
cirrhosis is closely related to ED, vWF as an indicator of ED causes considerable 
attention in cirrhotic patients. Since vWF is also involved in the pathogenesis and 
progression of PH, its value as a prognostic indicator in these patients becomes even 
more important.
vWF is a large multimeric glycoprotein released by the megakaryocytes and the 
activated vascular EC that plays a role in the process of primary hemostasis and 
coagulation [65]. In a coordinated manner, the function of vWF is regulated by 
two platelet membrane receptors, glycoprotein Ib (GPIb/IX/V) and glycoprotein 
IIb/IIIa [16, 66]. During primary hemostasis, vWF participates in both platelet 
adhesion and platelet aggregation. In case of endothelial damage, circulating vWF 
binds to exposed collagen in subendothelial structures and interacts with the 
platelet receptor GPIb/IX/V. This transient interaction enables subsequent stable 
interaction between platelets and collagen through the collagen receptor α2ẞ1 and 
glycoprotein VI [67]. This is followed by the exposure and activation of the receptor 
GP IIb/IIIa resulting in the release of platelet activating mediators such as Adenosine 
diphosphate (ADP) and TXA2. By binding to the GP IIb/IIIa receptor, the vWF 
participates in platelet aggregation and plug formation [16, 58]. Except in primary 
hemostasis, vWF also acts as a carrier of factor VIII protecting it from the proteo-
lytic action of protein C and its cofactor protein S [68, 69].
Human EC has the capacity to synthesize vWF multimers with a higher molecu-
lar weight called ultra-large molecular weight multimers (ULMWM) [70]. After 
secretion by the EC, ULMWM usually undergo a process of fractionation to smaller 
vWF forms that are normally present in the circulation [70–72]. vWF is continu-
ously secreted by the EC and megakaryocytes, while the ULMWM are stored in 
5
Endothelial Dysfunction and Systemic Inflammation in the Pathogenesis and Progression…
DOI: http://dx.doi.org/10.5772/intechopen.96172
the cytoplasmic granules and are released after their degranulation as a response 
to a significant endothelial damage [73]. Contrary to the small vWG multimers, 
ULMWMs are the most haemostatically active forms of vWF that have the property 
of spontaneous binding to platelets and subendothelial structures, and are consid-
ered prothrombotic [74]. The multimeric composition of vWF is regulated by its 
protease ADAMTS13 [67], a clearance metalloprotease synthesized in hepatic stel-
late cells [75, 76] that processes ULMWM into smaller vWF forms [67, 75, 76]. The 
vWF activity is strictly regulated by ADAMTS13 and the vWF reactivity towards 
platelets is proportional to the size of the vWF multimers [9]. Since ADAMTS13 
is synthesized in the liver [77], as expected, some studies have confirmed a mark-
edly reduced concentration of ADAMTS13 in patients with liver disease [78]. In 
some patients Lisman et al. also confirmed reduced ADAMTS13 concentration, 
but in others the concentration and activity of ADAMTS13 has been elevated [67]. 
This may be due to its reduced clearance of ADAMTS13 or its reduced release from 
platelets [79] as a consequence of platelet activation secondary to disseminated 
intravascular coagulation (DIC). Although in advanced liver disease the synthesis 
function of the hepatocytes is generally reduced, the stellate cells tend to have an 
increased synthetic activity [80, 81] which may also explain the increased synthesis 
of ADAMTS13 registered in some patients.
It has been established that intrahepatic and systemic ED is involved in the 
pathogenesis and progression of PH. Since vWF is an indicator of ED, vWF recently 
has gained an important role as a prognostic indicator in cirrhotic patients. There 
are many mechanisms that are related to the increased vWF production in cirrhotic 
patients. The intrahepatic production of vWF as a result of the intrahepatic ED has 
been confirmed by the positive immune staining of vWF in sinusoidal endothelial 
cells in these patients [82, 83]. Also, the presence of endotoxemia and bacterial 
products, especially in advanced diseases appear to be the most important cause of 
increased endothelial secretion of vWF [58, 67], which has been confirmed by the 
linear increase in vWF concentration with the increase of endotoxemia [58, 84]. In 
addition to the increased endothelial production of vWF, there are other mecha-
nisms that contribute to the increase in vWF such as increased shear stress, bacte-
rial infections [58, 85], neoplastic processes, physical activity, or interferon-based 
therapy [86, 87]. Decreased expression or activity of ADAMTS13 recorded in some 
cirrhotic patients may also result in reduced clearance and increased vWF concen-
tration [79]. It is also considered that increased vWF values may be related to the 
hyperfibrinolysis found in some patients, but on the other hand increased vWF has 
been also registered in patients without evidence of an increased proteolysis [58], 
which means that this is probably not a dominant mechanism.
Not only vWF is an indicator of ED, but the clinical and prognostic relevance of 
vWF is more pronounced because vWF is involved in the progression of PH. Since 
vWF is a large multimeric molecule, its increased concentration along with other 
abnormalities that favor procoagulant tendency in cirrhotic patients often results in 
occurrence of thrombosis in the hepatic microcirculation. If this is a long-term and 
continuous process, then it progressively obliterates and increases the resistance 
in the portal vasculature [67, 88] that leads to additional worsening of the PH. 
Additionally, it is assumed that when these thrombotic events are localized in the 
intestinal microcirculation they favor enterocytic ischemia and consequent intestinal 
bacterial translocation causing endotoxemia, which is crucial for the development of 
the majority of PH-related complications [9]. The literature data confirm a correla-
tion between the concentration of vWF and the HVPG values [7, 16] suggesting that 
vWF level reflects the degree of PH. Also, vWF level has been related to some compli-
cations of PH such as hepatopulmonary syndrome and esopgaheal varices [89, 90].
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The presence of PH is related to most of the complications in cirrhotic patients 
that define the course of the disease and more importantly the prognosis in these 
patients. Since vWF reflects PH, recent evidence emphasizes the importance of 
vWF as a predictor of mortality. Most studies that have analyzed the association 
between vWF and chronic liver disease have reported that vWF concentration 
correlates with the stage of liver disease assessed by Child-Turcotte-Pugh (CTP) and 
Model for End-Stage Liver Disease (MELD) score [7, 27, 91], that vWF can predict 
acute decompensation [16], occurrence of clinical events and PH-related compli-
cation [7, 92] and that vWF is an independent predictor of mortality that equals 
MELD score [7, 16, 91].
5.  The relation between systemic inflammation and adverse outcomes in 
cirrhotic patients and the prognostic role of C-reactive protein
It has been established that systemic inflammation (SI) is common in patients 
with advanced liver disease and PH [93] and that the presence of SI in these 
patients has been associated with adverse outcomes [94–96] and a poor prognosis 
[95, 97–99]. The negative impact of SI on liver disease is reflected mainly through 
the increase in the portal pressure and in the reduction of the hepatic blood flow i.e. 
through deterioration of PH and liver disease progression [100].
SI is defined as a state of persistent and inadequate stimulation of the immune 
system, which is manifested by the presence of elevated inflammatory cytokines 
and activated immune cells [101]. The presence of SI is usually assessed by the 
presence of systemic inflammatory response syndrome (SIRS), a set of hemody-
namic alteration that develops as a response to SI. The presence of SIRS is usually 
confirmed by specific diagnostic criteria. Sepsis is a condition of a systemic inflam-
matory response to infection, which involves a characteristic range of pathological 
changes in many host systems. The pathophysiological sequence involves release of 
cytokines and endothelial and neutrophil activation, which initiates a cascade of 
leukocyte-endothelial interaction and adhesion. This is followed by transendothe-
lial migration and subsequent microvascular and tissue damage, consequently lead-
ing to a multiple organ failure [102]. It has been reported that endothelial and tissue 
damage correlates with the intensity of the inflammatory response and leukocyte 
sequestration in tissues [103].
It is known that SIRS most commonly develops in the context of acute bacte-
rial infection. In patients with liver cirrhosis acute bacterial infection (respiratory, 
urinary etc.) can often cause an acute deterioration of liver function, which is mainly 
due to the effects of the SIRS. This may be a result of some specific features of the 
liver sinusoidal endothelial cells (SEC) that are not typical for the endothelial cells 
at other locations in the body. The liver SEC are fenestrated allowing inflammatory 
cells to pass through easily and come into direct contact with hepatocytes [104]. 
Additionally, the inflammatory cytokines within SI stimulate release of vWF from the 
EC [105, 106] and suppress the synthesis of ADAMTS13 in the stellate cells [105, 107] 
which may also contribute to the vWF rise and reflect the relation between SI and 
ED in cirrhotic patients. It has been also established that SI is underlying many of the 
PH-related complications and acute events in cirrhotic patients [93]. It is considered 
that in critically ill patients with liver cirrhosis, these acute events are better taken into 
account by the use of the general prognostic scores [Acute Physiology and Chronic 
Health Evaluation (APACHE) II, Sequential Organ Failure Assessment (SOFA), 
Simplified Acute Physiology Score (SAPS)], which provide better short-term mortal-
ity prediction than the prognostic scores specifically designed for patients with liver 
cirrhosis such as CTP and MELD score [9, 108]. On the other hand, some disorders 
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related to liver disease, PH or HC may modify the clinical and biochemical param-
eters included in the SIRS scores which decreases their value as SIRS indicators [95]. 
Hypersplenism may mask leukocytosis or exacerbate leucopenia; subclinical enceph-
alopathy may increase the respiratory rate and favor hypercapnia; hyperkinetic 
circulatory syndrome may increase the heart rate, and beta blockers may mask the 
tachycardia. This means that the presence of SIRS in patients with liver cirrhosis may 
often be underestimated by the scores and criteria for SIRS [93, 109]. Considering all 
the above, many researchers have focused on identifying new biological variables that 
would be more accurate indicators of SIRS than the currently used criteria. In this 
context, the value of serum C-reactive protein (CRP) as a surrogate marker of SIRS 
has recently been increasingly recognized [9].
CRP is an acute-phase inflammation protein that is synthesized in the liver 
mainly by interleukin 6. Moreover, it has been shown that CRP synthesis is pre-
served even in advanced liver disease [110, 111], which makes CRP a reliable SIRS 
indicator in this category of patients. Many researchers evaluated the predictive 
value of CRP in the general population and also in patients with liver cirrhosis. In 
the everyday clinical practice elevated CRP has been mainly used as an indicator of 
bacterial infection and many researchers have confirmed this relation [112–114]. 
Lazzarotto et al. defined that CRP value of 29.5 mg/L (sensitivity 82% and speci-
ficity 81%) is a reliable indicator of bacterial infection in cirrhotic patients [112]. 
Moreover, recent evidence suggests that the significant prognostic value of CRP in 
cirrhotic patients comes from the fact that in advanced liver cirrhosis, elevated CRP 
may persist after a bacterial infection has resolved [9] or it may also reflect the pres-
ence of a low grade SI that is not directly related to bacterial infection [108]. This is 
probably related to the endotoxemia and the bacterial products reaching systemic 
circulation.
The presence of SI in cirrhotic patients has the potential to trigger several 
serious complications and acute events related to PH and liver disease such as 
encephalopathy [68], renal failure [65, 70] or infection [108] and it has been related 
to negative outcomes during acute [115–117] or chronic [94–96] liver failure. Also, 
elevated CRP has been related to the organ failure and liver disease-related mortal-
ity [93, 112, 118]. Lazzarotto et al. confirmed that in patients with liver cirrhosis 
higher initial CRP values were associated with death before the ninetieth day of 
hospitalization [112]. Cervoni et al. demonstrated that mortality in liver cirrhosis 
was independently associated with CRP, MELD score, and extrahepatic comor-
bidities. They defined a CRP cut-off value of 29 mg/L persisting for 15 days after 
hospitalization to have the best sensitivity and specificity for predicting mortality 
in cirrhotic patients [93]. By using the variables found to be independent predictors 
of a six-month mortality (variations in CRP, MELD score and extrahepatic comor-
bidities) in the previous research [93], Di Martino et al. developed a prognostic 
model in order to predict the three-month mortality in patients with advanced liver 
cirrhosis and in a subgroup of patients with acute decompensation. They found that 
the MELD score [HR1.10; 95% CI, (1.05–1.14); P < 0.001] and mean CRP above 
32 mg/L at baseline or 15 days after hospitalization [HR 2.21; 95% CI (1.03–4.76), 
P = 0.042) were independent predictors of the three-month mortality. Moreover, 
the study showed better diagnostic efficacy of the prognostic model than the diag-
nostic efficacy of the MELD score (AUROC, 0.789 vs. 0.734; P = 0.043) [118]. Also, 
a positive correlation was registered between CRP and MELD score in the whole 
population, but such correlation was not registered in the subgroup of patients with 
end-stage liver disease. These findings suggested that the presence of SI was clini-
cally more significant in patients with advanced liver disease, that the prognostic 
significance of the CRP variations as indicators of SI was greater in more severe 
patients and that the presence of SI could not be adequately assessed by using the 
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MELD score. These findings once again emphasize the significant role of CRP as a 
prognostic indicator in patients with liver cirrhosis, especially in advanced disease.
6.  The relation between endothelial dysfunction, systemic inflammation 
and haemostatic abnormalities in chronic liver disease
The haemostatic process is a strictly regulated system in which the process of 
conversion of fibrinogen into fibrin is consequently followed by its subsequent 
degradation [119]. Since most coagulation factors and fibrinolytic proteins are 
synthesized in the liver, a proper hepatic function is of particular importance for 
the perfectly synchronized function of the haemostatic process. Hence, acute and 
chronic liver conditions often have an intense influence on the process of hemosta-
sis [120] and advanced liver disease is associated with many complex abnormalities 
in all three parts of the haemostatic process. In patients with liver cirrhosis the 
haemostatic dysfunction is related to several mechanisms, such as quantitative and 
qualitative platelet abnormalities, quantitative and qualitative abnormalities in the 
coagulation factors and fibrinolytic proteins, reduced clearance of activated coagu-
lation factors, abnormalities in the process of fibrinolysis, as well as to the presence 
of intensified fibrinolysis and low grade intravascular coagulation [121–123].
The primary hemostasis reflects the interaction between the platelets and the blood 
vessel and it is mediated by the action of vWF. Thrombocytopenia and the variable 
thrombocytopathy are the two most common abnormalities in cirrhotic patients within 
the primary hemostasis [124]. Thrombocytopenia occurs as a result of the increased 
sequestration due to splenomegaly, decreased thrombopoietin level and myelosuppres-
sion, increased systemic immune activation due to portosystemic shunting, impaired 
intestinal barrier and increased endotoxemia, immune-mediated platelet destruc-
tion and due to the platelet consumption within low grade intravascular coagulation 
[125–129]. The platelet dysfunction is presented as a reduced transmembrane signaling 
and progressive inability for platelet activation as a response to several stimuli such as 
adenosine diphosphate, thrombin, collagen, epinephrine or rhizocetine. This dysfunc-
tion results in insufficient production of thromboxane and serotonin and precipitates 
cascade abnormalities in the process of platelet aggregation [130, 131].
The central part of the haemostatic process is the process of coagulation, also 
called secondary homeostasis or thrombin generation. Most coagulation factors, 
such as fibrinogen, factor V, VII, VIII, IX, X, XI, XII are synthesized in the liver, 
which means if the liver synthetic function is impaired, their level inevitably 
decreases [132]. On the other hand, in patients with liver cirrhosis the synthesis of 
the anticoagulant proteins, such as protein C, protein S, and antithrombin is also 
reduced which partially compensate for the procoagulant deficiency. Despite the 
decreased concentration of most coagulation factors, in cirrhotic patients there is 
an increased concentration of factor VIII and vWF, two coagulation factors that 
are considered acute phase reactants [133–137]. Due to the reduced synthesis of 
the coagulation factors of the external pathway (mainly factor VII) prolonged 
prothrombin time (PT) is usually registered, while the reduced synthesis of the 
coagulation factors of the internal pathway results in prolongation of the activated 
partial thromboplastin time (aPTT). Thrombin time (TT) reflects the final step of 
the coagulation cascade, the conversion of fibrinogen into fibrin. TT reflects quan-
titative and qualitative fibrinogen abnormalities, a state called dysfibrinogenemia. 
Fibrinogen is also an acute phase reactant and in patients with mild or moderate 
liver cirrhosis it can be normal or slightly elevated [138, 139]. On the contrary, in 
advanced, severe cirrhosis fibrinogen concentration is usually decreased [139] 
resulting in prolongation of the TT. Fibrinogen is almost exclusively synthesized in 
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the liver and hypofibrinogenemia in these patients could be a consequence of the 
reduced synthetic liver capacity, the increased metabolism, the abnormal fibrino-
lytic activity or the consumption as part of the DIC [140].
The final phase of the haemostatic process is fibrinolysis, the process of thrombus 
dissolution that limits the coagulation cascade. The fibrinolytic impulse is generated 
by the tissue plasminogen activator (t-PA), uricinase plasminogen activator and acti-
vated factor XII. They induce the conversion of plasminogen to plasmin, which then 
acts on fibrin to produce the fibrin degradation products (FDP). Deviations in the 
fibrinolysis in cirrhotic patients occur as a result of the decreased hepatocyte func-
tion, vitamin K deficiency and presence of hyperfibrinolysis [48, 141] which has been 
registered in about one third of the cirrhotic patients [48, 142–144]. The presence of 
hyperfibrinolysis and DIC in patients with liver cirrhosis is still the subject of a wide 
debate [145]. According to some studies, the abnormalities in the hyperfibrinolitic 
process correlate with the CTP score and are more prevalent in the elderly and in 
patients with decompensated cirrhosis [146, 147]. Primary hyperfibrinolysis occurs 
due to the increased concentration of t-PA (as a consequence of impaired hepatic 
clearance) and decreased concentration or functionality of antiplasmin and other 
plasminogen activator inhibitors [148–151], which leads to an increased conversion 
of plasminogen to plasmin [152]. The secondary hyperfibrinolysis develops as a con-
tinuum of an emphasized coagulation, most commonly within DIC. Although DIC 
has been registered in a small number of patients with hyperfibrinolysis, it rarely has 
a significant clinical impact [152].
An important perspective of the hyperfibrinolysis in cirrhotic patients is its 
relation to the increased bleeding risk and to the increased incidence of portal vein 
thrombosis (PVT). FDP created during hyperfibrinolysis interfere with the process 
of fibrin polymerization by inhibiting the platelet aggregation and thus increasing 
the risk of bleeding. As the measurement of individual components of the fibrino-
lytic pathway is of little use in the assessment of this tendency, the role of hyperfi-
brinolysis in the pathogenesis of bleeding in patients with liver cirrhosis is still not 
completely clear [142]. On the other hand, the relation between elevated D-dimers 
and PVT in cirrhotic patients has also been evaluated. Most studies that analyzed 
the relation and prognostic role of D-dimers in these patients confirmed significant 
association between the elevated D-dimers and the occurrence of PVT [153, 154]. 
One study suggested that the risk of developing PVT in patients with liver cirrhosis 
was significantly higher in case of a significant postoperative rise in the D-dimers 
concentration that exceeded 16,000 ng/ml [153]. Zhang et al. confirmed significant 
association between the elevated D-dimers and the occurrence of PVT indepen-
dent of the CTP score [154]. Additionally, a meta-analysis of 21 studies found 
that increased concentration of D-dimers was associated with an increased risk of 
PVT not related to surgery, suggesting that D-dimers could be used as a diagnostic 
marker for PVT in cirrhotic patients [155]. However, not all studies confirmed this 
relation. A retrospective observational study of 66 patients did not find any signifi-
cant difference in the D-dimers level between cirrhotic patients with and without 
PVT [156]. Most studies suggest that elevated D-dimers in cirrhotic patients corre-
late with the degree of liver dysfunction which is probably related to the increased 
hyperfibrinolysis in advanced liver disease [144, 157, 158]. More importantly, it has 
also been established that in patients with liver cirrhosis elevated D-dimers were 
related to poor outcomes [144, 154, 157, 158] and that they were significant predic-
tor of short-term mortality [157, 158]. These findings suggest that in critically ill 
cirrhotic patients or in some specific clinical settings monitoring of the D-dimers 
concentration may have some useful clinical and prognostic implication.
It is well established that the significantly reduced synthetic liver function 
in advanced disease is responsible for the reduced synthesis of the coagulation 
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factors. But, since this occurs late in the stage of the disease, several other mecha-
nisms might be responsible for many complex abnormalities in the coagulation 
process in cirrhotic patients. In this context, the ED in patients with liver cirrhosis 
seems to be largely involved in this process through several mechanisms [48]. 
The process of ED by itself among other disturbances implies an imbalance in 
the secretion of pro-coagulants, anticoagulants, and also fibrinolytic substances, 
which can be responsible for some of the haemostatic abnormalities. Also, some 
evidence suggests that in patients with liver cirrhosis there is a direct relation 
between the endotoxemia and coagulation activity i.e. that endotoxemia can 
directly activates the coagulation and fibrinolytic pathway in patients with liver 
cirrhosis [159]. In this context, some researchers have demonstrated a strong 
association between endotoxemia and high levels of prothrombin fragments F1 + 2, 
which are markers of thrombin generation [159, 160], and also between endotox-
emia and elevated D-dimers, which are markers of hyperfibrinolysis [159]. This is 
confirmed by the fact that in cirrhotic patients with elevated F1 + 2 and D-dimers 
a reduction in the coagulation and fibrinolytic activity has been registered after 
reduction of endotoxemia [159]. Some data also confirm a direct association 
between endotoxin and a thrombin-antithrombin complex [160]. Endothelial 
activation may also explain the relationship between the synchronized rise of vWF 
and D-dimers as part of secondary hyperfibrinolysis. Lisman et al. extensively 
analyzed the qualitative and quantitative deviations of vWF in patients with liver 
cirrhosis and found elevated levels of propeptide indicating an acute endothelial 
damage, presumably associated to the presence of low grade DIC [67]. It is con-
sidered that the increased plasma proteolysis in these patients leads to increased 
concentrations of vWF as well as highly reactive vWF multimers [161, 162]. The 
endotoxin also has a potential to induce increased expression of tissue factor (TF) 
on the surface of the macrophages and to stimulate synthesis of tumor necrotic 
factor (TNF), which activates the external coagulation pathway [118, 163–165]. 
The presence of SI in cirrhotic patients also has an influence on the coagulation 
process. In terms of severe inflammation, the inflammatory cytokines activate the 
endothelial cells, inhibit the liver synthesis of protein C [166] and can stimulate 
degranulation of the cytoplasmic granules and release of ULMWM [105, 107], the 
most prothrombotic vWF multimers. Among other complex haemostatic abnor-
malities in cirrhotic patients, the increased concentration of ULMWM confirmed 
in some patients with acute decompensation [167] is considered to be related to the 
increased prothrombotic tendency.
7. Conclusion
All the above suggests a close relation between SI, ED, and liver disease-related 
coagulopathy in cirrhotic patients and emphasizes their important role in the 
pathogenesis of majority of manifestations and complications of PH. It also explains 
the crucial role of endotoxemia as a central initiating factor in their pathogenesis. 
Elevated vWF reflecting ED and significant and prolonged CRP rise reflecting SI 
should be routinely used in the everyday clinical practice. Additional research is 
needed in order to insert more deeply into the patogenesis of these entities and to pro-
pose new variables that would reflect their presence and significance more precisely.
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